May 2006
Volume 47, Issue 13
ARVO Annual Meeting Abstract  |   May 2006
Retinal Effects of Lutein and DHA on Diabetic Retinopathy
Author Affiliations & Notes
  • D. Domanico
    Ophthalmology, University of Rome "La Sapienza", Rome, Italy
  • E. Perrotta
    Ophthalmology, University of Rome, Rome, Italy
  • F. Montaldi
    Ophthalmology, University of Rome, Rome, Italy
  • I. Domanico
    Ophthalmology, University of Rome, Rome, Italy
  • E.M. Vingolo
    Ophthalmology, University of Rome, Rome, Italy
  • Footnotes
    Commercial Relationships  D. Domanico, None; E. Perrotta, None; F. Montaldi, None; I. Domanico, None; E.M. Vingolo, None.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 975. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      D. Domanico, E. Perrotta, F. Montaldi, I. Domanico, E.M. Vingolo; Retinal Effects of Lutein and DHA on Diabetic Retinopathy . Invest. Ophthalmol. Vis. Sci. 2006;47(13):975.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Angioprotective action of lutein and DHA was previously detected on diabetic patients, in which we obtained better retinal performances.The purpose of the study was to evaluate if drug association of lutein and DHA capsules may improve retinal microcirculation causing better performances in a group of diabetics patients.

Methods: : The study was conducted in double masked conditions. Randomized selection criteria were used to administer pharmaceutical preparations, half of which contained LDHA and half a placebo. We subjected 100 diabetic patients, from this group 30 IDDM patients were selected for this study with a double masked, randomized, cross–over design vs. fludarene. Were included in the study IDDM patients aged between 20 and 30 years and with refractive error, considered as spherical equivalent, below ± 6D.After a complete eye examination, computerized perimetry was performed with Humphrey Visual Field Analyzer (HFA).For each patient the duration of therapy was three months, compared with three months of fludarene. Patients were also monitored monthly with metabolic examinations. All patients were treated with LDHA once a day for three months and identical period of treatment with placebo, half of patients started with active drug while the other half started with placebo. All examination were repeated at month 3 and 6.

Results: : Considering the influence of treatment with LDHA on mean sensitivity of computerized perimetry, in treated patients we noted a significative increase of Mean Sensitivity value (p=0.000119), while fludarene group did not showed any change (p=NS). All treated patients showed a statistically significative reduction in SF (p=0.00008); conversely, the fludarene revealed only a slight significative change after treatment (p=0.02).Evaluating Color Vision tests with CCS, this index showed a significantly higher decrease in treated (P=0.02) patients than in placebo (p=NS). All these statistics showed a normally distributed error shift, and a highly significant Student’s "t" test evaluation between treatment vs. placebo group. Moreover all other ocular findings considered, BCVA, IOP and ophthalmoscopic appearance, did not showed significant changes between two groups.

Conclusions: : In our opinion treatment of LDHA produces improvement in retinal blood circulation, reduction in platelet aggregation, moreover it can favor hemorrhage re–absorption, so several studies have demonstrated the action of LDHA both as a capillary protector and on thrombocyte aggregation, and hence on thrombosis.

Keywords: diabetic retinopathy • diabetes • metabolism 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.